The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of low-dose radiotherapy (3 Gy\*4f) in indolent lymphoma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
73
Electron Beam/3D-CRT/IMRT/VMAT
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
RECRUITINGRate of clinical complete response after radiotherapy
complete resolution of disease in imaging or biopsy after low-dose radiotherapy
Time frame: 6-month after radiotherapy
Overall response rate after radiotherapy
complete or partial resolution of disease in imaging or biopsy after low-dose radiotherapy
Time frame: 6-month after radiotherapy
Progression-free survival rate at year 2 after enrollment, 2y-PFS
From enrollment to any disease progression or death
Time frame: 2-year
Local control rate at year 2 after enrollment, 2y-LCR
From enrollment to any local disease progression or death
Time frame: 2-year
Rate of acute toxicity (any and above grade 3)
toxicities according to CTCAE criteria
Time frame: From enrollment to 3 months after treatment
Rate of late toxicity (any and above grade 3)
toxicities according to CTCAE criteria
Time frame: After 3 months of enrollment
Quality of Life change, QoL
measurement basing on EORTC-QLQ-C30 tables
Time frame: 1/3/6/12/24 months after radiotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.